Aspire Biopharma closes $21M private placement, secures $22.5M credit facility for DCS acquisition

Aspire Biopharma Holdings, Inc.

Closed second tranche of $10M (12,500 preferred shares); total gross proceeds $21M from private placement.
Commitment letter for up to $22.5M senior secured credit facility to fund proposed $30M cash acquisition of DCS.
DCS (automotive supplier) had $200M+ revenue and $20M+ adjusted EBITDA in FY2025 (unaudited).
Stockholders' equity now exceeds $2.5M Nasdaq minimum; no new equity anticipated to consummate DCS purchase.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.